Plus Therapeutics announced on July 8, 2025, the treatment of its initial patients in the ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re 186 obisbemeda). This trial is designed for the treatment of leptomeningeal metastases (LM).
The dose optimization trial builds on promising results from the company’s completed Phase 1 single-dose escalation study, which demonstrated the feasibility of REYOBIQ for treating LM. The study aims to identify the optimal dosing regimen that maximizes efficacy and safety.
The trial is designed in alignment with the FDA’s Project Optimus. Researchers expect trial enrollment to proceed rapidly, assuming REYOBIQ continues its attractive safety profile, with all required patients and doses in Cohort 1 expected to be enrolled by the end of this year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.